Loading IDXX detail
Loading ticker data...
Loading IDXX detail
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide.
The company operates through CAG; Water Quality Products; LPD; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers.
IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Chart data unavailable
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has scheduled the release of its 2026 first quarter financial results for Tuesday, May 5, 2026, before the market opens. The Company will conduct an analyst conference call beginning at 8:30 a.m. ET on that day. Individuals can access a live webcast of the conference call, transcript of prepared remarks, and the Q1 2026 Earnings Snapshot through a link on the IDEXX website,.
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
WESTBROOK, Maine--(BUSINESS WIRE)--IDEXX Cancer Dx Panel with canine lymphoma detection helps clinicians investigate sooner and plan next steps with confidence.
Beacon Investment Advisory Services Inc. lifted its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 11.9% during the undefined quarter, according to its most recent disclosure with the SEC. The firm owned 62,951 shares of the company's stock after buying an additional 6,710 shares during the period. IDEXX Laboratories accounts for
Congress Asset Management Co. increased its position in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 9,894.0% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 153,908 shares of the company's stock after purchasing an additional 152,368 shares during the quarter. Congress
Procyon Advisors LLC bought a new stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) in the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 2,905 shares of the company's stock, valued at approximately $1,966,000. A number of other hedge funds have also recently
Achmea Investment Management B.V. grew its stake in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 319.9% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 17,769 shares of the company's stock after acquiring an additional 13,537 shares during the quarter.
Banco Bilbao Vizcaya Argentaria S.A. lifted its position in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 342.3% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 14,140 shares of the company's stock after purchasing an additional 10,943 shares during the quarter. Banco Bilbao Vizcaya
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
IDXX shares jump 39% in a year, as CAG Diagnostics' recurring revenues, diagnostic innovations and software growth fuel momentum.
Investors with an interest in Medical - Instruments stocks have likely encountered both SONOVA HOLDING (SONVY) and Idexx Laboratories (IDXX). But which of these two stocks is more attractive to value investors?
IDEXX Laboratories, Inc. (NASDAQ: IDXX - Get Free Report) EVP Nimrata Hunt sold 1,758 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $634.57, for a total value of $1,115,574.06. Following the completion of the sale, the executive vice president directly owned 18,141 shares
Barclays PLC reduced its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 22.4% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 236,670 shares of the company's stock after selling 68,510 shares during the quarter. Barclays PLC owned
B. Metzler seel. Sohn and Co. AG trimmed its holdings in IDEXX Laboratories, Inc. (NASDAQ: IDXX) by 20.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 16,947 shares of the company's stock after selling 4,388 shares during the quarter. B. Metzler seel.
